Novartis Reported Earlier, Its Phase III HARBOR Study Evaluating Del-Desiran In People Living With Myotonic Dystrophy Type 1 Did Not Meet Primary Endpoint

Loading news article.

Novartis Reported Earlier, Its Phase III HARBOR Study Evaluating Del-Desiran In People Living With Myotonic Dystrophy Type 1 Did Not Meet Primary Endpoint | WAPE

Novartis Reported Earlier, Its Phase III HARBOR Study Evaluating Del-Desiran In People Living With Myotonic Dystrophy Type 1 Did Not Meet Primary Endpoint

Article summary

Related companies

Comments —